Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A mid-stage trial shows islatravir plus Pifeltro shows promise as two-drug HIV regimen.
Young long-term survivors continue to face challenges.
The single-tablet regimen is now approved for previously treated people with an undetectable viral load.
The Department of Defense model of HIV care appears very successful, according to a recent study.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
Expanded access study confirms the long-acting monoclonal antibody works well in people with extensive prior treatment.
Which other cities have aimed for these targets, and how are they doing?
Long-acting injectables may be given once every other month, according to new findings.
Factors such as mental health and food security were associated with higher rates of successful HIV treatment among trans women.
Some groups, however, including Black and Latino men and homeless people, are not faring as well as others.
Cabotegravir plus rilpivirine maintenance therapy worked equally well when taken monthly or every two months.
Researchers compared experiences with stigma among Black women in Chicago and Birmingham.
Starting Symtuza quickly after HIV diagnosis is tied to high viral suppression.
A recent study found that factors such as mental health and food security were associated with higher rates of successful HIV treatment.
French study finds taking meds for four days with three days off is as effective as daily therapy—and costs 43% less.
Generalized anxiety disorder is associated with lower rates of HIV treatment, adherence to treatment and viral suppression.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.